Delayed vascular changes after antiangiogenic therapy with antivascular endothelial growth factor antibodies in human glioma xenografts in nude mice

Neurosurgery

Volumn 43, Issue 3, 1998, Pages 570-575

  Bernsen, Hans J J A ^a,c   Rijken, Paul F J W ^a   Peters, Johannes P W ^a   Bakker, Hans ^b   Van Der Kogel, Albert J ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Antiangiogenesis; Antivascular endothelial growth factor antibody; Glioma; Tumor vascularity

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; GLIOMA; IMMUNOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR VASCULARIZATION; VASCULARIZATION;

EID: 0031660845     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199809000-00094     Document Type: Article

References (30)

1. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H: Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor-121. Cancer Res 55:5296-5301, 1995.
2. Auerbach W, Auerbach R: Angiogenesis inhibition: A review. Pharmacol Ther 63:265-311, 1994.
3. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997.
4. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by antivascular endothelial growth factor neutralizing antibody. Cancer Res 56:4032-4039, 1996.
5. Devineni D, Kleinszanto A, Gallo JM: Uptake of tenozolomide in a rat glioma model in the presence or absence of the angiogenesis inhibitor TNP-470. Cancer Res 56:1983-1987, 1996.
6. Fan TD, Jaggar R, Bicknell R: Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 16:57-66, 1995.
7. Ferrara N, Houck K, Jakeman L, Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18-32, 1992.
8. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995.
9. Folkman J, Klagsbrun M: Regulators of angiogenesis. J Cell Biochem 47:199-200, 1991.
10. Gulledge CJ, Dewhirst MW: Tumor oxygenation: A matter of supply and demand. Anticancer Res 16:741-750, 1996.
11. Jain RK: 1995 Whitaker Lecture: Delivery of molecules, particles and cells to solid tumors. Ann Biomed Eng 24:457-473, 1996.
12. Kim KJ, Li B, Houck K, Winer J, Ferrara N: The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:53-64, 1992.
13. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS, Ferrara N: Inhibition of VEGF-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844, 1993.
14. Kondo S, Asano M, Suzuki H: Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth and its inhibition by the antibody. Biochem Biophys Res Commun 3:1234-1241, 1993.
15. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56:1615-1620, 1996.
16. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant. Nature 367:576-579, 1994.
17. Mu J, Abe Y, Tsutsui T, Yamamoto N, Tai XG, Niwa O, Tsujimura T, Sato B, Terano H, Fujiwara H, Hamaoka T: Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res 87:963-971, 1996.
18. Parenti A, Donnini S, Morbidelli L, Granger HJ, Ziche M: The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor. Br J Pharmacol 119:619-621, 1996.
19. Plate KH: Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Metastasis Rev 15:237-240, 1996.
20. Plate KH, Mennei HD: Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol 47:89-94, 1995.
21. Plate KH, Risau W: Angiogenesis in malignant gliomas. Glia 15:339-347, 1995.
22. Pötgens AJG, Lubsen NH, van Altena MC, Schoenmakers JCG, Ruiter DJ, de Waal RMW: Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 146:197-209, 1995.
23. Rijken PFJW, Bernsen HJJA, van der Kogel AJ: Application of an image analysis system for the quantitation of the tumor perfusion and vascularity in human glioma xenografts. Microvasc Res 50: 141-153, 1995.
24. Risau W: What, if anything, is an angiogenic factor? Cancer Metastasis Rev 15:149-151, 1996.
25. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M: Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55:1189-1193, 1995.
26. Senger DR, van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF: Vascular endothelial growth factor in tumor biology. Cancer Metastasis Rev 12:303-324, 1993.
27. Tsai JC, Goldman CK, Gillespie GY: Vascular endothelial growth factor in human glioma cell lines: Induced secretion by VEGF, PDGF-BB and bFGF. J Neurosurg 82:864-873, 1995.
28. Vaupel P: Blood flow and metabolic microenvironment of brain tumors. J Neurooncol 22:261-267, 1994.
29. Westphal JR, van't Hullenaar RGM, van der Laak JAWM, Cornelissen IMHA, Schalkwijk LJM, van Muijen GNP, Wesseling P, de Wilde PCM, Ruiter DJ, de Waal RMW: Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer 76:561-570, 1997.
30. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93:14765-14770, 1996.